We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

cell-1
cell-2
cell-3
cell-4
cell-5
cell-6

Spotlight

Curis Corporate Presentation

View our Current Corporate Presentation here.

Curis Corporate Presentation

Curis - VISTA

Press Releases

Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
CA-4948*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)

CA-4948*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)

Fimepinostat
HDAC/PI3K
 MYC-altered Cancers

Immune Checkpoint Inhibitors
CI-8993**
VISTA
 VISTA-expressing Cancers

CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing Cancers

CA-170*
VISTA/PDL1
 PDL1/VISTA-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
 Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
CA-4948*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)		Clinical Activity
CA-4948*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)		Clinical Activity
Fimepinostat
HDAC/PI3K
 MYC-altered CancersClinical Activity
Immune Checkpoint Inhibitors
CI-8993**
VISTA
 VISTA-expressing CancersSafety
CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing CancersProof of Principle
CA-170*
VISTA/PDL1
 PDL1/VISTA-expressing CancersClinical Activity
Approved Drug
Erivedge***
Hedgehog
 Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** Exclusive option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)